Investing.com - Erytech Pharma ADR reported on Monday second quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Erytech Pharma ADR announced earnings per share of $-0.5776 on revenue of $1.18M. Analysts polled by Investing.com anticipated EPS of $-0.643 on revenue of $1.49M.
Erytech Pharma ADR shares are up 28% from the beginning of the year and are trading at $6.390 , down-from-52-week-high.They are outperforming the S&P 500 which is up 16.02% from the start of the year.
Erytech Pharma ADR follows other major Healthcare sector earnings this month
Erytech Pharma ADR's report follows an earnings beat by Coloplast A on September 9, who reported EPS of $0.0926 on revenue of $761.44M, compared to forecasts EPS of $0.0911 on revenue of $772.29M.
Catalent Inc had beat expectations on August 30 with fourth quarter EPS of $1.16 on revenue of $1.19B, compared to forecast for EPS of $1.1 on revenue of $1.14B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar